



Office of Continuing Education

Please fill out the form below **IN INK** to verify participation in this CE activity and fax to 713-500-0606. If requesting Nursing credit please also complete the attached Post Test Questions

TOPIC: Session II: Emerging Bacterial/MRSA Infections

DATE: July 30, 2008

SPEAKER: Roy R. Chemaly, MD, MPH, FACP, FIDSA; Estil Vance, MD

LOCATION: Enduring Material

OBJECTIVES:

- Describe the epidemiology and pathophysiology of the most prevalent bacterial strains that cause nosocomial and community based SSTI
- Differentiate between patients at high- and low-risk of infection and evaluate appropriate prophylaxis and therapeutic options for each group

DISCLOSURE:

Dr. Chemaly receives Grant/Research Support from Wyeth, Pfizer, ViroPharma Inc., and Roche. He is a Consultant for Wyeth and Ortho-McNeil. He is on the Speakers Bureau for Astra-Zeneca, Pfizer, Wyeth, Cubist Pharmaceuticals and Merck.

Dr. Vance wishes to disclose that his wife is on the Speakers Bureau for Pfizer and Johnson & Johnson. Any money earned from her speaking engagements are contributed to local charities and do not directly contribute to their income.

Accreditation: This program has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Texas Medical Branch at Galveston and Oncology Today. The University of Texas Medical Branch at Galveston is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME The University of Texas Medical Branch at Galveston designates this educational activity for a maximum of (1.25) *AMA PRA Category 1 Credit(s)*TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CNE This program has been approved by the American Association of Critical Care Nurses (AACN) for 1.0 Contact Hour, Category A, File Number 2008 - (1181b).

ACPE The University of Houston College of Pharmacy (UHCOP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing education. Pharmacists documenting completion of the program "Infections in Cancer Patients: Prevention and Management in the Community Care Setting-Emerging Bacteria/MRSA Infections (066-999-08-013-L01-P) by signing in and completing evaluations will receive 1 contact hour (0.1 CEU) pharmacy continuing education credit, and will receive a statement of credit by mail within 3 weeks of UHCOP being notified of the completion date. Initial release date: April 15, 2008. Expiration date: 4/15/2011.

CREDIT CANNOT BE AWARDED UNLESS FORM IS COMPLETELY LEGIBLE

First Name	MI	Last Name	Title
Address:			
City:	State:	Zip:	
Phone:	Fax:	Email:	

PLEASE COMPLETE EVALUATION FORM BEFORE RETURNING

- Make solid marks that fill the response completely.
- Make no stray marks on this form.

Scale: 1= Strongly Disagree 2= Disagree 3= Agree 4= Strongly Agree

①	②	③	④	The content of this presentation is applicable to my professional development.
①	②	③	④	The course objectives were met.
①	②	③	④	The presentation was clear and understandable.
①	②	③	④	The program was free of commercial bias and presented in an objective manner.
①	②	③	④	The presentation was scientifically based and accurate.
①	②	③	④	As a result of this course, my professional effectiveness will increase.

Disagree ←————→ Agree

Comments for strengths and improvements: _____



Name _____

Please complete the following questions if requesting nursing or pharmacy credit.

Session II: Emerging Bacterial/MRSA Infections Post-test

What are the major limitations of using vancomycin?

- a) It has limited activity against staphylococci embedded in biofilms
- b) It is inferior to b-lactam for treating MSSA bacteremia
- c) The risk of VRE and VRSA emergence
- d) All the above

Please fax completed forms to 713-500-0606